FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980226857> ?p ?o ?g. }

• W2980226857 endingPage "5548" @default.
• W2980226857 startingPage "5534" @default.
• W2980226857 abstract "// Jamie M. Aye 1 , Laura L. Stafman 2 , Adele P. Williams 2 , Evan F. Garner 2 , Jerry E. Stewart 2 , Joshua C. Anderson 3 , Smitha Mruthyunjayappa 2 , Mary G. Waldrop 2 , Caroline D. Goolsby 2 , Hooper R. Markert 2 , Colin Quinn 2 , Raoud Marayati 2 , Elizabeth Mroczek-Musulman 4 , Christopher D. Willey 3 , Karina J. Yoon 5 , Kimberly F. Whelan 1 and Elizabeth A. Beierle 2 1 Department of Pediatrics, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL, USA 2 Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA 3 Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA 4 Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA 5 Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL, USA Correspondence to: Jamie M. Aye, email: jaye@peds.uab.edu Keywords: kinase inhibition; Wilms tumor Received: May 21, 2019     Accepted: August 12, 2019     Published: September 17, 2019 ABSTRACT Aggressive therapies for patients with metastatic Wilms tumor (WT) with subsequent severe late effects warrant the search for novel therapies. The role of focal adhesion kinase (FAK), a non-receptor tyrosine kinase important in pediatric solid tumor development and progression, has not been examined in metastatic WT. Using a novel patient-derived xenograft (PDX) of a primary and matched, isogenic, metastatic WT, the hypothesis of the current study was that FAK would contribute to metastatic WT and small molecule inhibition would decrease tumor growth. Immunohistochemical staining, immunoblotting, cell viability and proliferation assays, cell cycle analysis, and cellular motility and attachment-independent growth assays were performed. FAK was present and phosphorylated in both WT PDXs and in the human samples from which they were derived. FAK inhibition decreased cellular survival, proliferation, and cell cycle progression in both PDXs but only significantly decreased migration, invasion, and attachment-independent growth in the primary WT PDX. Kinomic profiling revealed that platelet-derived growth factor receptor beta (PDGFR&#x03B2;) may be affected by FAK inhibition in WT. Pharmacologic inhibition of FAK and PDGFR&#x03B2; was synergistic in primary WT PDX cells. These findings broaden the knowledge of metastatic WT and support further investigations on the potential use of FAK and PDGFR&#x03B2; inhibitors." @default.
• W2980226857 created "2019-10-18" @default.
• W2980226857 creator A5017334354 @default.
• W2980226857 creator A5019652492 @default.
• W2980226857 creator A5025228395 @default.
• W2980226857 creator A5028871812 @default.
• W2980226857 creator A5030726262 @default.
• W2980226857 creator A5031418334 @default.
• W2980226857 creator A5035598310 @default.
• W2980226857 creator A5046084575 @default.
• W2980226857 creator A5047513471 @default.
• W2980226857 creator A5053849505 @default.
• W2980226857 creator A5055934732 @default.
• W2980226857 creator A5060882257 @default.
• W2980226857 creator A5067067884 @default.
• W2980226857 creator A5075780491 @default.
• W2980226857 creator A5078320545 @default.
• W2980226857 creator A5080570482 @default.
• W2980226857 creator A5085928277 @default.
• W2980226857 date "2019-09-17" @default.
• W2980226857 modified "2023-10-16" @default.
• W2980226857 title "The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor" @default.
• W2980226857 cites W1043464252 @default.
• W2980226857 cites W1567758522 @default.
• W2980226857 cites W1673643619 @default.
• W2980226857 cites W1751752696 @default.
• W2980226857 cites W1824799279 @default.
• W2980226857 cites W1838430124 @default.
• W2980226857 cites W1973268693 @default.
• W2980226857 cites W1973371898 @default.
• W2980226857 cites W1975866732 @default.
• W2980226857 cites W1987371632 @default.
• W2980226857 cites W1988698591 @default.
• W2980226857 cites W1989901777 @default.
• W2980226857 cites W1990158722 @default.
• W2980226857 cites W2006145157 @default.
• W2980226857 cites W2023249455 @default.
• W2980226857 cites W2024792557 @default.
• W2980226857 cites W2025508421 @default.
• W2980226857 cites W2025721244 @default.
• W2980226857 cites W2030692297 @default.
• W2980226857 cites W2031501894 @default.
• W2980226857 cites W2041310270 @default.
• W2980226857 cites W2042454040 @default.
• W2980226857 cites W2043686550 @default.
• W2980226857 cites W2055021586 @default.
• W2980226857 cites W2058637024 @default.
• W2980226857 cites W2058682042 @default.
• W2980226857 cites W2059716736 @default.
• W2980226857 cites W2068652698 @default.
• W2980226857 cites W2076230995 @default.
• W2980226857 cites W2085691401 @default.
• W2980226857 cites W2096439168 @default.
• W2980226857 cites W2103894337 @default.
• W2980226857 cites W2105611672 @default.
• W2980226857 cites W2109227311 @default.
• W2980226857 cites W2111173668 @default.
• W2980226857 cites W2120220319 @default.
• W2980226857 cites W2120272982 @default.
• W2980226857 cites W2123334268 @default.
• W2980226857 cites W2131827371 @default.
• W2980226857 cites W2132966617 @default.
• W2980226857 cites W2140662194 @default.
• W2980226857 cites W2154409731 @default.
• W2980226857 cites W2155466614 @default.
• W2980226857 cites W2157706519 @default.
• W2980226857 cites W2158769524 @default.
• W2980226857 cites W2163738584 @default.
• W2980226857 cites W2165172311 @default.
• W2980226857 cites W2168159338 @default.
• W2980226857 cites W2222356376 @default.
• W2980226857 cites W2296687919 @default.
• W2980226857 cites W2342679175 @default.
• W2980226857 cites W2395212701 @default.
• W2980226857 cites W2465543890 @default.
• W2980226857 cites W2498524830 @default.
• W2980226857 cites W2525561198 @default.
• W2980226857 cites W2528438395 @default.
• W2980226857 cites W2590280648 @default.
• W2980226857 cites W2598927934 @default.
• W2980226857 cites W2794353845 @default.
• W2980226857 cites W2914232272 @default.
• W2980226857 cites W2938524649 @default.
• W2980226857 cites W4237120103 @default.
• W2980226857 cites W4244491773 @default.
• W2980226857 doi "https://doi.org/10.18632/oncotarget.27165" @default.
• W2980226857 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6756857" @default.
• W2980226857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31565187" @default.
• W2980226857 hasPublicationYear "2019" @default.
• W2980226857 type Work @default.
• W2980226857 sameAs 2980226857 @default.
• W2980226857 citedByCount "4" @default.
• W2980226857 countsByYear W29802268572022 @default.
• W2980226857 countsByYear W29802268572023 @default.
• W2980226857 crossrefType "journal-article" @default.
• W2980226857 hasAuthorship W2980226857A5017334354 @default.
• W2980226857 hasAuthorship W2980226857A5019652492 @default.
• W2980226857 hasAuthorship W2980226857A5025228395 @default.

• next